AstraZeneca rejoins leading US drug lobby group Ruchika Sharma23 April 2025 9:30 AM ISTAstraZeneca has rejoined the Pharmaceutical Research and Manufacturers of America (PhRMA), the main U.S. drug lobby group, nearly two years...
AstraZeneca Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer Ruchika Sharma4 April 2025 3:30 PM ISTCambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union...
AstraZeneca gets USFDA approval for perioperative Imfinzi for bladder cancer Ruchika Sharma1 April 2025 2:15 PM ISTImfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.
AstraZeneca, Harbour BioMed join hands to discover, develop next-generation therapeutic antibodies Ruchika Sharma25 March 2025 9:30 AM ISTCambridge: Harbour BioMed, a global biopharmaceutical company has announced a global strategic collaboration with AstraZeneca to discover and develop...
AstraZeneca, Alteogen ink pact for subcutaneous formulations of multiple oncology assets Ruchika Sharma18 March 2025 10:30 AM ISTCambridge: AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme...
AstraZeneca to acquire EsoBiotec for up to USD 1 billion Ruchika Sharma17 March 2025 3:30 PM ISTCambridge: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies...
AstraZeneca Imfinzi approved in EU for limited stage small cell lung cancer Ruchika Sharma17 March 2025 10:30 AM ISTThe safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.
AstraZeneca Imfinzi based perioperative regimen recommended for approval in EU for resectable non-small cell lung cancer Ruchika Sharma4 March 2025 10:15 AM ISTAstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for...
AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer Ruchika Sharma3 March 2025 12:15 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union...
AstraZeneca Gets CDSCO Panel Nod To study Baxdrostat Tablets and Dapagliflozin Tablets Dr. Divya Colin7 Feb 2025 6:00 PM ISTNew Delhi: AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation...
Roche bags USFDA nod for companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for Enhertu Ruchika Sharma1 Feb 2025 12:30 PM ISTBasel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5)...
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA approval for HER2-ultralow metastatic breast cancer Ruchika Sharma28 Jan 2025 2:30 PM ISTAstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with...
